Gilead Sciences waded further into the immunology and inflammation (I&I) disease space on Thursday with the proposed purchase of PepStar Therapeutics' IL-23R inhibitor programme, which includes lead candidate HCXT-2001, in Phase I testing. The US drugmaker is splashing $1.28 billion in upfront cash to gain the asset, an oral macrocyclic peptide inhibitor of IL-23R with an extended half-life. The acquisition is expected to close this quarter. According to Gilead, IL-23R is a clinically validated

Italy's Menarini has struck a global licensing deal with US biotech Georgiamune centred on GIM-621, a preclinical-stage small molecule designed to harness the immune system against several types of solid tumours. Georgiamune will receive $45 million in upfront and near-term payments, with the deal's total value reaching $1.1 billion if the potential first-in-class drug clears a series of milestones. The biotech is also eligible for royalties on future sales. "This programme is a strong complemen

Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolumab alone, reducing the risk of disease progression or death by 27% Median progression-free survival was 11.7 months with HBI-8000 plus nivolumab compared with 7.4 months with nivolumab alone The safety profile of HBI-8000 was consistent with experience from its use in more than 112,000 patients treated in other cancers If approv

Alcon on Wednesday spent $550 million to acquire Neurotech Pharmaceuticals, gaining its encapsulated cell therapy for macular telangiectasia type 2 (MacTel), a rare eye disease where blood vessels in the macula become dilated and leak, causing central vision loss. Encelto (revakinagene taroretcel-lwey) was greenlit in the US last year, making it the only FDA-approved treatment for MacTel. After surgical intravitreal implantation, the therapy continuously releases recombinant human ciliary neurot

Approval based on phase III data showing unprecedented functional cure rates compared to standard of care Six-month treatment with option of self-administration after first dose CHB affects approximately 1.7 million people in the US1 GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (Nr

Eli Lilly has formed a partnership with Hong Kong's Metis TechBio worth up to $1.1 billion, gaining access to an AI drug delivery platform designed to improve therapeutic performance of drugs carried by lipid nanoparticles. The collaboration will center on Metis' ionizable lipid discovery and optimization platform called AiLNP, which the company touts as the “world's first and only de novo lipid generation algorithm,” relying on a large lipid library, end-to-end screening and a lipid language mo

NIGMS SBIR Phase II award will support development of an AI-powered metabolomics foundation model designed to unify insights across metabolomics data and accelerate therapeutic discovery through Sinopia's LEADS® platform Sinopia Biosciences, Inc., a biotechnology company leveraging multi-omics data, high-throughput screening, and artificial intelligence to identify and develop first-in-class therapies for diseases with significant unmet need, today announced it has been awarded a $2.5 million S

Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy

On October 19, 2026, the first patients in the Phase 1/2 clinical trial ATL001-PII-CEP received their first dose and will continue on a daily oral dose over the coming months. On October 19, 2026, the first three patients with congenital erythropoietic porphyria (CEP) enrolled in the ATL001-PII-CEP clinical trial received their first dose of ATL-001, Atlas Molecular Pharma’s investigational oral drug for CEP. This is the first timeATL-001 h as been given to people with this severe, ultra-rare d

Oral olorofim was non-inferior to AmBisome® followed by standard of care (AmBisome®+SOC), with Day 42 all-cause mortality of 23.8% for olorofim versus 24.3% for AmBisome®+SOC in patients with invasive aspergillosis1 Enrolled patients had invasive aspergillosis for which standard mould-active azole therapy was either not appropriate (known or suspected azole resistance, intolerance to azole therapy, drug-drug interactions, or breakthrough infection while on azole) or had been ineffective1 Fewer p